CJC-1295 (DAC) is a long-acting growth hormone releasing hormone (GHRH) analog designed for advanced research applications involving growth hormone regulation, endocrine signaling, and metabolic pathway studies.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic tetrasubstituted peptide derived from growth hormone releasing hormone (GHRH 1-29). The addition of DAC technology significantly extends the peptide’s half-life, allowing sustained interaction with growth hormone pathways, making it a valuable compound in longevity, metabolism, and endocrine research.
Due to its ability to support prolonged growth hormone secretion through controlled receptor stimulation, CJC-1295 DAC is frequently utilized in scientific studies examining protein synthesis pathways, recovery mechanisms, cellular repair processes, and metabolic regulation.
Its extended stability compared to shorter-acting GHRH analogs makes it particularly useful in laboratory environments where consistent exposure and predictable pharmacokinetic behavior are required for research analysis.
Manufactured under strict quality control protocols, CJC-1295 DAC is produced as a high-purity lyophilized peptide suitable for professional research applications.
Key Research Characteristics
• Long-acting GHRH analog
• DAC technology for extended half-life
• High purity lyophilized peptide
• Designed for endocrine and metabolic research
• Stable formulation for laboratory use
• Consistent research-grade quality standards
Important Notice
This product is intended strictly for research and laboratory use only. Not for human consumption, therapeutic applications, or diagnostic use. This material should only be handled by qualified professionals in controlled research settings.
High-quality research-grade peptides and compounds engineered for scientific innovation and laboratory use.